- Home
- HUMA vs CLLS Comparison
HUMA vs CLLS Comparison
Compare HUMA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | CLLS |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 139.0M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HUMA | CLLS |
|---|---|---|
| Price | $0.60 | $1.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $1.64 | ★ $4.83 |
| AVG Volume (30 Days) | ★ 5.3M | 87.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,038,000.00 | N/A |
| Revenue This Year | $78.59 | N/A |
| Revenue Next Year | $570.06 | $10.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.88 |
| 52 Week High | $1.53 | $5.45 |
Technical Indicators
Market Signals| Indicator | HUMA | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 55.13 |
| Support Level | $0.54 | $1.31 |
| Resistance Level | $0.61 | $2.99 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 85.43 | 69.12 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.